Lipocine Inc (LPCN)

04:32 AM

Press Release Distribution & PR Platform - ACCESS Newswire

04:32 AM

Apr 24, 2025

Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.

Apr 24, 2025

Apr 23, 2025

StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World

Apr 23, 2025

Apr 18, 2025

Lipocine Receives Updated Regulatory Guidance on LPCN 1154 (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 15, 2025

Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 15, 2025

Apr 07, 2025

Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com - Defense World

Apr 07, 2025

Apr 03, 2025

Lipocine Inc. Reports 2024 Financial Turnaround - TipRanks

Apr 03, 2025

Mar 27, 2025

Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Yahoo

Mar 27, 2025

Mar 26, 2025

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - MarketScreener

Mar 26, 2025

Mar 22, 2025

StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World

Mar 22, 2025

Mar 21, 2025

Testosterone, TRAVERSE, And A Label Change 15 Years In The Making - News & Insights

Mar 21, 2025

Mar 13, 2025

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Quantisnow

Mar 13, 2025

Mar 13, 2025

Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results - StockTitan

Mar 13, 2025

Mar 12, 2025

Lipocine to change FDA labeling for testosterone products -March 12, 2025 at 09:59 am EDT - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Lipocine Announces FDA Labeling Changes for Testosterone Products - Citizentribune

Mar 12, 2025

Mar 12, 2025

Lipocine announces FDA labeling changes for testosterone products - TipRanks

Mar 12, 2025

Mar 12, 2025

FDA Lifts Critical Cardiovascular Warning for Testosterone Treatments: Major Win for Lipocine - StockTitan

Mar 12, 2025

Mar 06, 2025

Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - The AM Reporter

Mar 06, 2025

Mar 04, 2025

LPCN stock touches 52-week low at $2.92 amid market challenges By Investing.com - Investing.com South Africa

Mar 04, 2025

Mar 04, 2025

LPCN stock touches 52-week low at $2.92 amid market challenges - Investing.com UK

Mar 04, 2025

Mar 03, 2025

Lipocine Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

Mar 03, 2025

Mar 01, 2025

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Marketscreener.com

Mar 01, 2025

Feb 27, 2025

Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World

Feb 27, 2025

Feb 26, 2025

Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World

Feb 26, 2025

Feb 11, 2025

Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World

Feb 11, 2025

Feb 08, 2025

Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World

Feb 08, 2025

Feb 07, 2025

Lipocine plans phase 3 study for postpartum depression drug - MSN

Feb 07, 2025

Feb 06, 2025

Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com

Feb 06, 2025

Feb 06, 2025

Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa

Feb 06, 2025

Feb 06, 2025

Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal

Feb 06, 2025

Feb 02, 2025

Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World

Feb 02, 2025

Jan 28, 2025

Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart

Jan 28, 2025

Jan 20, 2025

Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World

Jan 20, 2025

Jan 12, 2025

(LPCN) On The My Stocks Page - Stock Traders Daily

Jan 12, 2025